Research Topics
| P GreenbergSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokinesP Greenberg
VA Palo Alto Health Care System and Stanford University Medical Centre, CA 94305, USA
Ann Rheum Dis 60:iii41-2. 2001..Further studies are warranted using anti-TNFalpha/anti-inhibitory cytokine approaches, either alone or in combination with other agents, capable of abrogating the effects of additional inhibitory mechanisms in MDS...
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)Peter L Greenberg
Hematology Division, Stanford University Medical Center, 703 Welch Rd, Suite G 1, Stanford, CA 94305, USA
J Clin Oncol 22:1078-86. 2004....
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabinePeter L Greenberg
Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
Leuk Lymphoma 54:321-8. 2013....- Revised international prognostic scoring system for myelodysplastic syndromesPeter L Greenberg
Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
Blood 120:2454-65. 2012..As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease... - Molecular and genetic features of myelodysplastic syndromesP L Greenberg
Hematology Division, Stanford University Cancer Center, Stanford, CA, USA
Int J Lab Hematol 34:215-22. 2012..Use of more comprehensive and sensitive methods for molecular profiling using 'next-generation' sequencing techniques for MDS marrow cells will likely further define critical biologic lesions underlying this spectrum of diseases... - Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromesPeter L Greenberg
Division of Hematology, Stanford University Cancer Center, Stanford, CA 94305, USA
Leuk Res 34:1560-5. 2010.... - Current therapeutic approaches for patients with myelodysplastic syndromesPeter L Greenberg
Hematology Division, Stanford University Cancer Center, Stanford, CA 94305 5821, USA
Br J Haematol 150:131-43. 2010..The rationale for use of low versus high intensity therapies with these agents, including allogeneic haematopoietic stem cell transplantation, is discussed in detail... - Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)Peter L Greenberg
Stanford University Cancer Center, CA 94305, USA
Blood 114:2393-400. 2009..In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation... - The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network GuidelinesPeter L Greenberg
Stanford University Cancer Center, Stanford, California 94305 5821, USA
J Natl Compr Canc Netw 6:942-53. 2008..The economic impact of drug therapy should be weighed against the patient's potential for improvement in clinical outcomes, quality of life, and transfusion requirements... - Myelodysplastic syndromes: iron overload consequences and current chelating therapiesPeter L Greenberg
Hematology Division, Stanford University Cancer Center, 875 Blake Wilbur Drive, Room 2335, Stanford, CA 94305 5821, USA
J Natl Compr Canc Netw 4:91-6. 2006..These outcomes could potentially alter the tissue siderosis-associated morbidity of patients with MDS, particularly those with pre-existing cardiac disease... - Management of patients with higher risk myelodysplastic syndromesJon S Fukumoto
Division of Hematology, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305 5821, USA
Crit Rev Oncol Hematol 56:179-92. 2005..This paper reviews the various therapeutic options for higher risk MDS, providing rationale for specific management approaches for these patients... - A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromesJason Gotlib
Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
Am J Hematol 84:15-20. 2009..Our data indicate that weekly weight-based dosing of DA, with the addition of G-CSF in selected individuals, can be an effective erythropoietic option in a high proportion of lower-risk MDS patients... - Myelodysplastic syndromes clinical practice guidelines in oncologyPeter L Greenberg
Stanford Hospital and Clinics, Stanford, CA, USA
J Natl Compr Canc Netw 4:58-77. 2006 - Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) studyAthena M Cherry
Department of Pathology, Stanford Hospital and Clinics, Stanford, CA 94305, USA
Leuk Res 27:1085-90. 2003..In addition, it appears that interphase FISH studies are nearly as sensitive as cytogenetic analyses and can be a useful tool in studying bone marrow aspirates where cytogenetic analysis is not possible... - International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromesJelena M Kao
Division of Hematology, Stanford University Cancer Center, Stanford, California 94305 5821, USA
Am J Hematol 83:765-70. 2008..This information should prove useful for aiding therapeutic decision-making, prognostic classification, and designing clinical trials for patients with MDS... - Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progressionKunju Sridhar
Hematology Division, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Blood 114:4847-58. 2009.... - Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza
Rush University Medical Center, Chicago, IL, USA
Blood 111:86-93. 2008..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality... - Chronic myelogenous leukemiaEllin Berman
J Natl Compr Canc Netw 3:732-55. 2005 - A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet
H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
Blood 109:1387-94. 2007..Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response... - Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson
Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA
Blood 108:419-25. 2006..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria... - Chronic myelogenous leukemiaEllin Berman
University of Texas M. D. Anderson Cancer Center, USA
J Natl Compr Canc Netw 5:474-96. 2007 - A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi
Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
Blood 111:2589-96. 2008..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...